Effects of ulinastatin on expression pattern of high mobility group box-1 protein and CD4+ CD25+ regulatory T cells in rats with scald injury

HONGMING YANG*, CHAO HU*, YONGMING YAO†, JIAKE CHAI†, MA LI†, FENG YONGQIANG†, CHU WANLI†

1First Hospital Affiliated to the Chinese PLA General Hospital, Beijing, PR China
2Beijing Luhe Hospital, Capital Medical University, Beijing, PR China
*Hongming Yang and Chao Hu contributed equally to this work.

Abstract

Aim of the study: To observe the effects of ulinastatin on T lymphocyte immune function and the expression of high mobility group box-1 protein (HMGB1) in rats with scald injury.

Material and methods: A total of 96 Wistar rats were randomly divided into three groups (32 rats in each group): sham burn group (S), burn group (B), ulinastatin-treated group (BU).

Sham-burned rats were immersed in distilled water at 37 °C for 12 seconds and served as control, rats in the later two groups were inflicted with 30% TBSA full thickness burns at boiling water (94 °C) for 12 seconds, followed by resuscitation with Ringer’s solution (i.p.). The treatment group (BU) received ulinastatin and the control group was given the same amount of saline solution immediately following burn injury, wounds in rats were soaked in 1% povidone-iodine solution. Blood samples and spleens were collected at 1, 3, 5, 7 d after injury for further laboratory investigations. High mobility group box-1 protein expression was evaluated by western blotting, the presence of CD4+ CD25+ regulatory T cells were determined with flow cytometry, the plasma IL-4 and IFN-γ levels were determined using ELISA.

Results: Compared with the S group (0.22 ± 0.05), during postburn days 1 to 7, the level of HMGB1 in splenic tissue was significantly elevated in the B group (p < 0.01), reached the maximum at 3 d after injury (0.66 ± 0.10, p < 0.01). After treated with ulinastatin, HMGB1 level was markedly decreased, reached the lowest value at 5 d (0.32 ± 0.07, p < 0.01). Compared with the sham burn group, percentage of CD4+ CD25+ Treg cells in B group gradually increased after injury and peaked at 3 d after injury (5.42% ± 0.56%). After burn injury 1, 5, 7 d, percentage of CD4+ CD25+ Treg cells in BU group was significantly lower than the B group (p < 0.01), reached the lowest at 5 d (2.23% ± 0.21%). The serum level of IFN-γ in B group was significantly higher than the S group (p < 0.01), IL-4 was significantly higher than that of the S group (p < 0.01). After injury for 1–7 d, the content of IFN-γ in BU group were significantly higher than the B group (p < 0.05 or p < 0.01), and IL-4 level was significantly lower than the burn group (p < 0.05 or p < 0.01).

Conclusions: As an anti-inflammatory drug, ulinastatin effectively reduced the expression of HMGB1 in the spleen tissue of severely burned rats, which was associated with reduction in the level of regulatory T cells (Treg), and the functional polarization of splenic T cells levels and Th1/Th2 pattern changes. Taken together these data suggested that ulinastatin improved the immune function of rats with scald injury.

Key words: high mobility group box-1 protein, regulatory T cells, HMGB1, scald, ulinastatin, immunity.

Introduction

CD4+ T cells have been subdivided into at least three functional Th subsets on the basis of their cytokine production, including Th1, Th2 and regulatory T (Treg) cells [1]. Especially, Treg cells, which are a subset of T lymphocytes that play critical role in immunological suppression and the termination of immune responses, and deficiency or dysfunction of these cells can lead to inflammatory and autoimmune diseases [2-5]. Tregs are broadly classified into two subsets: natural or adaptive (induced). Natural Tregs are CD4+CD25+ T-cells which develop and emigrate from the thymus to perform their key role in immune homeostasis. Based on CD25 expression, natural Tregs comprise 5-10% of peripheral CD4+ T cells, and CD4+CD25+ Tregs have been found to suppress autoimmune T cell responses and reduce inflammation in a series of autoimmunity disorders [6]. CD4+CD25+ Tregs are important mediators of the suppression of T cell activation and the reduction in Th1 cytokine production found after injury [7].

High-mobility group box-1 (HMGB1) is a nuclear non-histone DNA-binding protein that functions as a structural co-factor in gene transcription in somatic cells. Recent studies indicate that damaged or necrotic cells can release HMGB1 into the extracellular milieu, where it triggers inflammatory responses [8]. It was noted that serum levels of HMGB1 were increased in experimental burn injury models, and anti-HMGB1 antibodies decreased the severity of burn injury [9], demonstrating a vital role for HMGB1 in this pathophysiological process. It was reported that the excessively released HMGB1 could stimulate CD4+CD25+ Tregs activity and trigger a shift of Th1 to Th2 with suppression of T-lymphocyte immune function after burn injury [10].

After severely burned, low levels of anti-inflammatory mediators and excessive expression of proinflammatory mediators leads to excessive inflammatory response, resulting in immune cell dysfunction and weak immune response [11]. The low-level of immune response is considered to be an important mechanism in the development of sepsis after burn injury (trauma). The purpose of the modern immunomodulation therapy is to prevent the body’s inflammatory response caused by the immune intermediates into sepsis. Modulation of the Th1/Th2 balance has become a new paradigm for immunomodulatory therapy. Effective immunomodulation therapy is considered a fundamental breakthrough of sepsis treatment [12].

Ulinastatin, which is also known as urinary trypsin inhibitor, is a glycoprotein that was first detected in human blood and it functions as a broad-spectrum proteinase inhibitor. The inhibition of trypsin, a-chymotrypsin, elastase, and various pancreatic enzymes by ulinastatin has been previously reported [13, 14]. The administration of ulinastatin was reported to be effective in the treatment of acute pancreatitis, and a series of clinical trials have been carried out to confirm the safety and efficacy of the drug [15]. In clinical studies the most common side effects reported following intravenous administration of ulinastatin included skin rashes and angialgias at the injection site, abdominal symptoms, elevated liver enzymes, and other abnormalities in serum tests [16]. Anti-inflammatory effect of ulinastatin in septic rats has been confirmed [17], but the immune modulatory effects of ulinastatin remain to be elucidated. Its anti-inflammatory effects include suppressed production of the pro-inflammatory cytokines IL-6, IL-8, and TNF-α, as well as reduced neutrophil infiltration [14]. The present study aimed to investigate the therapeutic effects of ulinastatin (intraperitoneally injected) on the expression of HMGB1 in rats with scald injury, the percentage of CD4+CD25+ Treg cells and the functional polarization of effector T cells. Our results provided the experimental basis for application of ulinastatin in treating immune dysfunction caused by excessive inflammation.

Material and methods

Reagents and equipments

Fluorescein isothiocyanate (FITC)-conjugated anti-rat antibody CD4, FITC-conjugated anti-mouse IgG2b (isotype control), phycoerythrin (PE)-conjugated anti-rat CD25 and PE-conjugated IgG2a (isotype control) were purchased from BD Pharmingen, USA. Recombinant HMGB1 proteins were purchased from Sigma (USA). Hemolyisin was purchased from BD Pharmingen (USA). ELISA kits were purchased from R&D Systems (USA). FACSCalibur flow cytometer was purchased from BD Pharmingen (USA). Ulinastatin was purchased from TianPu biochemical pharmaceutical Co., Ltd. (China, National Medical License Number H19990134).

Animal model

Ninety-six Wistar rats of SPF level, weighing 180-200 g, were purchased from the Beijing Vital River Lab Animal Co., Ltd, were housed in separate cages in a temperature- and humidity-controlled room with 12 h light and 12 h darkness, to acclimatize for at least 7 days before being used. All animals had free access to water but were fasted for 12 hours before the experiment. Wistar rats were randomly divided into three groups (32 rats in each group): sham burn group (S), burn group (B), ulinastatin-treated group (BU). All of these groups were further divided into four subgroups of eight rats each and they were killed on post-burn days (PBD) 1, 3, 5, 7, respectively. Rats were anesthetized with intraperitoneal injection of pentobarbital sodium (60 mg/kg), and the animals’ backs were shaved with 20% sodium sulfide. In the burn group (B) and ulinastatin-treated group (BU) rats, a full skin thickness burn injury was produced in anesthetized rats by exposing 30% of total
body surface area to 94°C water for 12 s, and the animals’ wounds were covered with 20 g/l iodophors twice a day [18, 19]. All the test animals were quickly dried after each exposure to avoid additional injury. The sham group rats were subjected to all of the procedures, except the temperature of the bath was at room temperature. Lactated Ringer solution (40 ml/kg) was administered intraperitoneally for delayed resuscitation 6 h after the injury and 4 ml at 12, 24, 36, 48, 60, 72 h after the burn injury. Ulinastatin (4 × 10^4 U/kg) was added to lactated Ringer solution in the ulinastatin-treated groups. The wake animals after anesthesia were housed in separate cages, and were sacrificed on at designated time points, blood samples and spleens were collected, liquid nitrogen frozen and stored at −80°C until further use. All experimental protocols were undertaken in accordance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals, with the approval of the scientific investigation board of the Burn Institute, Postgraduate Medical College, Beijing, China.

**Western blot analysis of HMGB1**

Expression of HMGB1 was analyzed by Western blotting as described previously. Spleen tissue lysate was prepared by homogenization in lysis buffer and the supernatant was collected after centrifugation at 14,000 r/min for 30 min (4°C). The protein concentration was determined by BCA assay. For western blotting, samples (30 µg) of total cell proteins were separated by SDS-PAGE, semi-dry transferred to polymembrane, after blocked by 5% defatted milk, the membrane was incubated with HMGB1 antibody (anti-rabbit, diluted 1:1000) overnight at 4°C, washed and incubated with goat anti-rabbit antibody (1:2000), washed and visualized with an enhanced chemiluminescence substrate (Pierce, Rockford, Ill), exposed to X-ray film according to the manufacturer’s instructions and scanned into a image scanner (LEICA Q-550IW; Wetzlar, Germany). Band intensities were quantified using National Institutes of Health Image 1.59 software and relative levels of HMGB1 were normalized to that of the 30 pmol purified recombinant HMGB1 intensity (Sigma), which was run on each gel.

**Flow cytometric analysis**

Blood samples (100 µl) were collected from abdominal aorta, treated with a hemolysis buffer (17 mM Tris-HCl and 140 mM NH4Cl, pH 7.2) to remove red blood cells, stained with both FITC-conjugated anti-CD4 (5 µg) and PE-conjugated anti-rat CD25 (5 µg), incubated in the dark for 20 minutes (4°C), appropriate PE- or FITC-conjugated irrelevant monoclonal antibody of the same Ig class was used as isotype control. Samples were washed twice with PBS, centrifuged at 1300 r/min and fixed in 1% paraformaldehyde. Isotype control antibody staining was used to set gates, numbers in gates reflect the percentage of positive cells. Flow cytometry data were analyzed using the CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA).

**Interleukin 4, interferon γ measurements by ELISA**

Serum IL-4, IFN-γ levels were determined by ELISA, according to manufacturer’s instructions. After enzyme substrate reaction was terminated, the absorbance of the yellow reaction mixture at 450 nm was then read using a microplate reader, a standard curve was produced with mean values of 6 duplicates in which absorbance values for blank tubes had been subtracted. The concentration of cytokines in samples could be calculated according to the standard curve.

**Statistical analysis**

Data were expressed as mean ± standard deviation (SD) and analyzed with a one-way ANOVA. A Student-test was used to evaluate significant differences between groups. A p value of 0.05 or less was considered to be statistically significant.

**Results**

**Animal mortality**

The total experimental animal number is 96, and the number of animals that were included in the final grouping is 92. Group U and S did not result in any mortality during the first 72 h of study. The animals in B group had an approximate 9.4% mortality in the same period. Most of the mortality occurred between 48 and 72 h.

**HMGB1 expression pattern in spleen of all groups**

HMGB1 expression was analyzed by western blotting. Compared with the S group (0.22 ±0.05), during PBDs 1 to 7, the relative expression level of HMGB1 in splenic tissue was significantly elevated in the B group (p < 0.01), peaking on PBD 3 (0.66 ±0.10, p < 0.01). After treated with ulinastatin, HMGB1 level was markedly decreased, reached the lowest value on PBD 5 (0.32 ±0.07, p < 0.01), while relative expression level of HMGB1 in B group was 0.63 ±0.07. There was statistical significance between B groups and BU groups on PBD 1, 5, 7 (Fig. 1), while there was no obvious change between B groups and BU groups on PBD 3 (Fig. 1 and Fig. 2).

**CD4+CD25+ Treg expression**

A previous study in burnt mice showed that on days 1, 3 and 5 after injury, the highly purified population of splenic CD4+CD25+ T cells were predominately FoxP3+ Tregs, with approximately 70% of these cells staining positive for FoxP3 [10]. Therefore, we focused our current study on CD4+CD25+ T cells, which are predominately Tregs and not activated T cells. Flow cytometry analysis was per-
formed to evaluate the percentage of CD4+CD25+ Treg cells following treatment with ulinastatin or saline in burnt rats. It was observed that, compared with the S group, during PBDs 1 to 7, percentage of CD4+CD25+ Treg cells in B group gradually increased after injury (t-value = 2.83, 15.14, 5.45 and 22.26, respectively) and it reached the lowest expression levels on day 5 (2.23% ±0.21%). Each value represents the mean ± SD of at least three measurements. The group B and group BU vs. the group S, a p < 0.01. Group S and the group BU vs. the group B, b p < 0.01.

Fig. 3. Percentages of CD4+CD25+ Tregs

Interleukin 4 and interferon γ expression

The serum level of IFN-γ in B group was significantly higher than the S group (p < 0.01), while IL-4 was significantly higher than that of the S group (p < 0.01). After injury for 1–7 d, the content of IFN-γ in BU group were significantly higher than the B group (p < 0.05 or p < 0.01), and IL-4 level was significantly lower than the B group (p < 0.05 or p < 0.01) (Table 1).

Discussion

Ulinastatin is a broad-spectrum protease inhibitor that is effective against a broad range of enzymes such as trypsin, hyaluronidase and other pancreatic enzymes. It has been used as a drug for patients with disseminated intravascular coagulation, shock, and pancreatitis in Japan [8-10]. Ulinastatin was observed to have the lysosomal membrane-stabilizing property and reduce the production of oxygen free radicals. Our results demonstrated that the percentage of regulatory CD4+CD25+ T lymphocytes (Treg) was elevated in severely burned rats, and peaked at 3 d after injury. Compared with the sham burn group, different expression levels of CD4+CD25+ Tregs in ulinastatin-treated group were observed, but significantly lower than those in burn group, indicating that the percentage of CD4+CD25+ Tregs was decreased in burnt rats after treated with ulinastatin.

CD4+CD25+ Tregs could efficiently induced type 2 T-cell polarization as demonstrated by the changes in IL-4/IFN-γ ratio, which is an indicator of Th1/Th2 balance, indicating that lower the expression of CD4+CD25+ Tregs might efficiently induce type 1 T-cell polarization, thus improving the immune function and reduce the risk of sepsis [20].

It was reported that the relative balance between IFN-γ (Th1-type cytokine) and IL-4 (Th2-type cytokine) cytokines appeared crucial in the outcome of infections, IL-4 played critical role in modulating the Th1/Th2 cell polarization [21, 22]. Serum IFN-γ (Th1 cytokine) concentration of the burned mice decreased, while serum levels of IL-4 (Th2 cytokine) were elevated, thus promoted the Th2 polariza-
tion [23-25]. Serious injury induced a shift to the Th-2 phenotype with increased production of IL-4 rather than generalized Th suppression [26]. In present study, serum levels of IFN-\(\gamma\) in the group B was significantly higher than the group S (\(p<0.01\)), while serum levels of IL-4 was significantly higher than the group S (\(p<0.01\)), indicating the percentage of Th2 polarized cells increased. After the BU group was treated with ulinastatin, the serum levels of IL-4 significantly decreased during PDBs 1 to 5, while serum levels of IFN-\(\gamma\) significantly elevated during PDBs.

**Fig. 4.** FACS analysis of CD4+CD25+ Treg on PBD 3

**Fig. 5.** Enzyme-linked immunosorbent assay of the IL-4 and IFN-\(\gamma\) levels in serum after injury (\(n=8\), pg/ml)
1 to 7, demonstrating that ulinastatin efficiently induced Th1 cell polarization and the immune status was improved.

HMGB1 secreted as an important late-phase inflammatory mediators involved in the pathophysiological process of sepsis [27-29]. However, the mechanism of HMGB1 synthesis and release after burn injury is still unclear, which may be associated with rapid release of various cytokines and endotoxin translocation under acute stress. Some studies showed that serum levels of HMGB1 were significantly elevated in patients with trauma or sepsis, which was associated with poor prognosis of patients, indicating that HMGB1 was closely related with occurrence of immune dysfunction and sepsis [30], providing new ideas and methods to combat immune dysfunction in sepsis. Studies have found that HMGB1 of severely burned rats may affect the inhibitory activity of regulatory T lymphocytes through RAGE (Receptor for Advanced Glycation End products), suppressed the proliferative response of T lymphocytes, played critical role the maturation process of CD4+CD25+ Treg in spleen of severely burned rats following delayed resuscitation, and mediated the subsets of T lymphocytes (T helper cells) differentiate into Th2 phenotype, then induced the inhibitory effects on immune function. To explore whether ulinastatin could inhibit the expression of HMGB1, as well as lead to decreased CD4+CD25+ Treg levels and Th1/Th2 pattern changes, we investigated the expression pattern of proinflammatory factor HMGB1 in burned rats. In this study confirmed that the levels of HMGB1 in spleen of burned rats were significantly elevated during PBDS 1 to 7 d, peaking on PBD 3, and HMGB1 levels on PBD 7 were higher than in 5 d. We speculated that severely burned rats were given only resuscitation and anti-inflammatory treatment, lack of the necessary anti-inflammatory therapy and anti-inflammatory support, the wound was still healing (wound debridement and healing stage), all these factors lead to the HMGB1 level increased again on PBD 7. After treated with ulinastatin, the expression levels of HMGB1 were significantly decreased compared with burn group, suggesting that ulinastatin as anti-inflammatory drug effectively inhibited HMGB1 synthesis and release. In present study, the percentage of CD4+CD25+ Treg levels and inhibit Th2 cytokine profile (increased IFN-γ and decreased IL-4 production), either directly or indirectly via the suppression of HMGB1 release.

In conclusion, our data support a putative role for ulinastatin-mediated suppression of HMGB1 expression pattern. Hence, we hypothesized that ulinastatin could efficiently suppress CD4+CD25+ Treg levels and inhibit Th2 cytokine profile (increased IFN-γ and decreased IL-4 production), either directly or indirectly via the suppression of HMGB1 release.

References

Effects of ulinastatin on expression pattern of high mobility group box-1 protein and CD4+ CD25+ regulatory T cells in rats with scald injury

20. Riley JL, June CH, Blazar BR (2009): Human T regulatory cells as therapeutic agents: take a billion or so of these and call me in the morning. Immunity 30: 656-665.